Fingerprint
Dive into the research topics of 'A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically